Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy

Abstract Objectives To assess the predictive and prognostic value of changes in longitudinal neutrophile-to-lymphocyte (NLR) ratios in men receiving taxane-based chemotherapy for metastatic prostate cancer (PC). Methods Retrospective, unicentric cohort study of patients treated with either docetaxel...

Full description

Bibliographic Details
Main Authors: Manuel Neuberger, Christel Weiß, Nora Goly, Janina Skladny, Katja Nitschke, Frederik Wessels, Karl F. Kowalewski, Frank Waldbillig, Friedrich Hartung, Malin Nientiedt, Luisa Egen, Jonas Herrmann, Jonas Jarczyk, Margarete Teresa Walach, Maximilian C. Kriegmair, Niklas Westhoff, Thomas S. Worst, Philipp Nuhn
Format: Article
Language:English
Published: Springer 2022-12-01
Series:Discover Oncology
Subjects:
Metastatic hormone-sensitive prostate cancer (mHSPC)
Metastatic castration-resistant prostate cancer (mCRPC)
Docetaxel
Cabazitaxel
Biomarkers
Prognosis
Online Access:https://doi.org/10.1007/s12672-022-00603-0

Internet

https://doi.org/10.1007/s12672-022-00603-0

Similar Items